Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Integral Diagnostics Ltd. ( (AU:IDX) ) has shared an announcement.
Integral Diagnostics Ltd. announced the release of 965,141 fully paid ordinary shares from voluntary escrow on 1 September 2025, which will not affect the company’s issued capital. This move is part of the company’s ongoing operational strategies, potentially impacting its market dynamics and stakeholder interests.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The company employs some of Australasia’s leading radiologists and diagnostic imaging specialists, focusing on quality patient care, service, and access through a unique medical leadership model.
Average Trading Volume: 1,034,732
Technical Sentiment Signal: Buy
Current Market Cap: A$1.01B
See more insights into IDX stock on TipRanks’ Stock Analysis page.